Recent Updates
Recently added Catalysts
ARGX Positive Sentiment Score: 70/100

argenx announces Extraordinary General Meeting of Shareholders on November 18, 2025

Friday, October 3, 2025 2 min read
Key Takeaway: argenx SE has announced an Extraordinary General Meeting of shareholders scheduled for November 18, 2025, in Amsterdam. The meeting will address the adoption of a revised remuneration policy. Shareholders are encouraged to attend in person or vote by proxy, with relevant documents available on the company's website.

Market Sentiment Analysis

POSITIVE FACTORS

  • Announcement of an Extraordinary General Meeting indicates active shareholder engagement.
  • Proposed adoption of a revised remuneration policy shows commitment to corporate governance.
  • Encouragement for electronic voting reflects modern practices in shareholder participation.

Full Press Release Details

October 3, 2025

Amsterdam, the Netherlands– argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the Extraordinary General Meeting of shareholders will be held at 14:00 CET on Tuesday, November 18, 2025 at the offices of Freshfields LLP (Netherlands), Strawinskylaan 10, 1077 XZ Amsterdam, the Netherlands.The shareholders and all other persons with meeting rights are invited to attend the Extraordinary General Meeting of shareholders. The formal notice of convocation (including information on attending the meeting in person or by proxy, requirements for notification and registration for the meeting and regarding the e-voting system) is available on the argenx websitewww.argenx.comand onwww.abnamro.com/evoting.
Agendaargenx has proposed the adoption of a revised remuneration policy during the meeting. The agenda for the meeting as well as all ancillary documents relevant for the meeting are available via the argenx website and are also available for inspection at the argenx offices. A free copy thereof may also be obtained by e-mailinglegal@argenx.com. argenx would like to encourage shareholders to use the voting by (electronic) proxy option as referred to in the convocation.
About argenxargenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visitwww.argenx.comand follow us onLinkedIn,Instagram,Facebook, andYouTube.

For further information, please contact:

Media:

Ben PetokBPetok@argenx.com

Investors:

Alexandra Royaroy@argenx.com

Frequently Asked Questions

When is the Extraordinary General Meeting of argenx?

The Extraordinary General Meeting of argenx is scheduled for November 18, 2025.

Where will the meeting take place?

The meeting will be held at Freshfields LLP, Amsterdam, Netherlands.

What is on the agenda for the meeting?

The agenda includes the proposal for a revised remuneration policy.

How can shareholders participate in the meeting?

Shareholders can attend in person or vote by proxy, with details available online.

Tags: ARGX Viatris Investor Conferences Healthcare argenx extraordinary general meeting shareholders remuneration policy Amsterdam
Last updated: Oct 3, 2025